Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, Russian Phase II trial in 196 patients, 40 mg of LY2140023 twice daily met the primary
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury